Skip to main content

REVIEW article

Front. Pharmacol.
Sec. Cardiovascular and Smooth Muscle Pharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1451445
This article is part of the Research Topic Strategies to Overcome Metabolic Syndrome and Related Diseases View all 15 articles

Role of Naringin in the Treatment of Atherosclerosis

Provisionally accepted
Yan LU Yan LU *De-Hong Li De-Hong Li Ji-Mei Xu Ji-Mei Xu *Sheng Zhou Sheng Zhou *
  • Gansu Provincial Hospital, Lanzhou, China

The final, formatted version of the article will be published soon.

    Atherosclerosis (AS) is a major pathological basis of coronary heart disease. However, the currently available medications are unable to effectively reduce the incidence of cardiovascular events in the majority of patients with AS. Therefore, naringin has been attracting considerable attention owing to its anti-AS effects. Naringin can inhibit the growth, proliferation, invasion, and migration of vascular smooth muscle cells, ameliorate endothelial cell inflammation and apoptosis, lower blood pressure, halt the cell cycle at the G1 phase, and impede growth via its antioxidant and free radical scavenging effects. These activities suggest the potential anti-AS effects of naringin. In this review article, we comprehensively summarized the latest findings on the anti-AS effects of naringin and their underlying mechanisms, providing a crucial reference for future research on the anti-AS potential of this agent.

    Keywords: Naringin, Atherosclerosis, vascular smooth muscle cell, endothelial cell, Inflammation, antioxidant

    Received: 19 Jun 2024; Accepted: 29 Aug 2024.

    Copyright: © 2024 LU, Li, Xu and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Yan LU, Gansu Provincial Hospital, Lanzhou, China
    Ji-Mei Xu, Gansu Provincial Hospital, Lanzhou, China
    Sheng Zhou, Gansu Provincial Hospital, Lanzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.